Graft Versus Host Disease clinical trials at UC Irvine

1 research study open to eligible people

Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
open to eligible people ages 18 years and up
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Orange 5379513, California 5332921 and other locations

Last updated: October 23, 2025